Analysis for BAX

📈 Growth & Financial Trajectory

Over the eight quarters, Baxter's Revenues rose from about $2.70B in 2024 Q2 to about $2.96B in 2026 Q2, a modest uptrend despite volatility. Net income fluctuated, ending at $126M in 2026 Q2 after a mid-2024 peak and a sharp drop in 2025 Q4. The pattern shows topline growth with uneven profitability, including a sizable Q4 2025 loss before a rebound.

💰 Margins & Cash Flow

Gross margin hovered in the mid-30s, with Gross Margin ≈ 34-35%. Operating margins were mixed, positive in several quarters but negative in 2025 Q3–Q4. Cash flow from operating activities remained generally positive in multiple quarters (e.g., 2025 Q1–Q2, 2026 Q2), while investing and financing activities produced outsized outflows reflecting ongoing capital allocation.

🛡️ Balance Sheet & Liquidity

Total assets run around $21-27B, with Equity ~ $7-8B and Long-term debt ~ $9-10B in mid-2025. Liabilities are well-supported by assets, indicating solid liquidity cushions, though leverage warrants monitoring given debt levels.

⚠️ Key Drivers & Risks

• Drivers: Healthcare demand, ongoing device R&D, favorable utilization trends.
• Risks: Earnings volatility from quarter to quarter, regulatory/reimbursement shifts, and valuation sensitivity to margin recovery.